Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.
In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™for all indicationsmatching the reference product ...
Le Lézard22h
Teva and Alvotech Announce SELARSDItm (ustekinumab-aekn) Injection Now Available in the U.S.
In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDItm for all indications matching the reference product Stelara® (ustekinumab) and has granted a provisional determination ...
No more needles? Startups are testing patches to deliver weight-loss drugs and other medications.
Local companies are developing technologies that they hope could replace a painful poke with something that feels more like ...
pharmaphorum5d
So it begins: Next Humira biosimilars launch in US
Indications for which Humira’s regulatory exclusivity have already lapsed include rheumatoid arthritis, Crohn’s disease, plaque psoriasis, ulcerative colitis, and hidradenitis suppurativa.
ETF Daily News6d
Best Biotech Stocks To Keep An Eye On – February 14th
The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease ...
pharmaphorum2d
AbbVie's Skyrizi beats IL-23 rivals to Crohn's disease approval
AbbVie's IL-23 inhibitor Skyrizi trailed some of its rivals in its first indication psoriasis ... inhibitors including AbbVie's own blockbuster Humira (adalimumab). Meanwhile, Eli Lilly's IL ...
Biotech Stocks To Consider – February 16th
Danaher, Recursion Pharmaceuticals, Moderna, Thermo Fisher Scientific, AbbVie, Vertex Pharmaceuticals, and Cognizant Technology Solutions are the seven Biotech stocks to watch today, according to ...